Levothyroxine in Pregnancy Did Not Affect Neonatal Admission Rates
Women being treated with levothyroxine were administered a daily morning dose throughout pregnancy starting 4-8 days after her first prenatal visit.
Male thyroid cancer survivors have a nearly 50 percent higher risk of developing CVD than female survivors within five years of cancer diagnosis.
LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.
Compared with uninfected individuals, people with HIV controlled with combination antiretroviral therapy are not at increased risk of developing thyroid dysfunction.